rofecoxib has been researched along with Coronary Artery Disease in 4 studies
Coronary Artery Disease: Pathological processes of CORONARY ARTERIES that may derive from a congenital abnormality, atherosclerotic, or non-atherosclerotic cause.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In this study, we investigated the effects of both 25 and 50 mg daily doses of rofecoxib on the endothelial functions of patients with coronary artery disease (CAD)." | 9.11 | Selective COX-2 inhibition with different doses of rofecoxib does not impair endothelial function in patients with coronary artery disease. ( Bayindir, P; Bayturan, O; Ekmekçi, C; Tikiz, C; Tikiz, H; Utük, O, 2005) |
| "The aim of this study was to determine whether selective cyclooxygenase-2 (COX-2) inhibition with rofecoxib can modulate endothelial dysfunction and levels of circulating inflammatory markers in patients with established coronary artery disease (CAD)." | 9.10 | Effect of cyclooxygenase-2 inhibition with rofecoxib on endothelial dysfunction and inflammatory markers in patients with coronary artery disease. ( Giddens, K; McInerney, MM; McQueen, MJ; Nassar, BA; Title, LM, 2003) |
| "In this study, we investigated the effects of both 25 and 50 mg daily doses of rofecoxib on the endothelial functions of patients with coronary artery disease (CAD)." | 5.11 | Selective COX-2 inhibition with different doses of rofecoxib does not impair endothelial function in patients with coronary artery disease. ( Bayindir, P; Bayturan, O; Ekmekçi, C; Tikiz, C; Tikiz, H; Utük, O, 2005) |
| "The aim of this study was to determine whether selective cyclooxygenase-2 (COX-2) inhibition with rofecoxib can modulate endothelial dysfunction and levels of circulating inflammatory markers in patients with established coronary artery disease (CAD)." | 5.10 | Effect of cyclooxygenase-2 inhibition with rofecoxib on endothelial dysfunction and inflammatory markers in patients with coronary artery disease. ( Giddens, K; McInerney, MM; McQueen, MJ; Nassar, BA; Title, LM, 2003) |
| " Naproxen users had the lowest adjusted rates of serious coronary heart disease (myocardial infarction, coronary heart disease death) and serious cardiovascular disease (myocardial infarction, stroke)/death from any cause, with respective incidence rate ratios (relative to NSAID nonusers) of 0." | 3.75 | Cardiovascular risks of nonsteroidal antiinflammatory drugs in patients after hospitalization for serious coronary heart disease. ( Arbogast, PG; Castellsague, J; Chung, CP; Daugherty, JR; García-Rodríguez, LA; Murray, KT; Ray, WA; Stein, CM; Varas-Lorenzo, C, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ray, WA | 1 |
| Varas-Lorenzo, C | 1 |
| Chung, CP | 1 |
| Castellsague, J | 1 |
| Murray, KT | 1 |
| Stein, CM | 1 |
| Daugherty, JR | 1 |
| Arbogast, PG | 1 |
| García-Rodríguez, LA | 1 |
| Title, LM | 1 |
| Giddens, K | 1 |
| McInerney, MM | 1 |
| McQueen, MJ | 1 |
| Nassar, BA | 1 |
| Tikiz, C | 1 |
| Utük, O | 1 |
| Bayturan, O | 1 |
| Bayindir, P | 1 |
| Ekmekçi, C | 1 |
| Tikiz, H | 1 |
| Rashid, A | 1 |
| Dale, G | 1 |
| Hennebry, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase IIa Randomized, Active-controlled, Double-blind, Dose-escalation Study in Patients With Vulvovaginal Candidiasis to Evaluate Dose Response Relationship of Clinical Efficacy, Safety and Tolerability of Topically Administered ProF-001[NCT03115073] | Phase 2/Phase 3 | 84 participants (Actual) | Interventional | 2017-04-04 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for rofecoxib and Coronary Artery Disease
| Article | Year |
|---|---|
Effect of cyclooxygenase-2 inhibition with rofecoxib on endothelial dysfunction and inflammatory markers in patients with coronary artery disease.
Topics: Aspirin; Biomarkers; Brachial Artery; Coronary Artery Disease; Cyclooxygenase Inhibitors; Double-Bli | 2003 |
Selective COX-2 inhibition with different doses of rofecoxib does not impair endothelial function in patients with coronary artery disease.
Topics: Aged; Brachial Artery; Coronary Artery Disease; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclo | 2005 |
2 other studies available for rofecoxib and Coronary Artery Disease
| Article | Year |
|---|---|
Cardiovascular risks of nonsteroidal antiinflammatory drugs in patients after hospitalization for serious coronary heart disease.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cohort Studies; C | 2009 |
Cold leg in patient with high coated platelets: possible association with the use of rofecoxib.
Topics: Acute Disease; Blood Platelets; Coronary Artery Disease; Cyclooxygenase 2 Inhibitors; Eptifibatide; | 2006 |